Tag: CAR-T

Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


CAR T-Cell Research Surges

  Nov 15 2020 Tagged CAR-T

Research on chimeric antigen receptor (CAR) T-cell therapies has exploded since the first such treatment received approval in 2017. Hundreds of trials are under way, 3 therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma (MM).

Read more
Immunotherapy Web Featured Images 27

Bispecific anti-CD20 and anti-CD19 CAR T Cell Therapy Shows Efficacy in B Cell M...

Nirav N. Shah, MD, an associate professor at the Medical College of Wisconsin, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor (CAR) T cells in a phase 1 dose escalation and expansion trial (NCT03019055) for relapsed B cell malignancies.

Read more

Unanswered Questions Remain in DLBCL With Use of CAR T-Cell Therapies

In an interview with Targeted Oncology, Caron Jacobson, MD, discussed the data supporting use of CAR T-cell therapy as treatment of patients with diffuse large B-cell lymphoma and some of the remaining questions in this space that need to be addressed as these cellular therapies advanced forward in the field.

Read more
Immunotherapy Web Featured Images 11

CRS in CAR-T course freely available on the EHA Campus

  Nov 03 2020 Tagged CAR-T

The CRS in CAR-T module, part of the 8-course EHA Campus program dedicated to CAR-T cells, is now freely accessible by everyone - even non-EHA members. The course covers all aspects of Cytokine Release Syndrome (CRS), from pathophysiology to appropriate management. As this main complication of CAR-T cell therapy requires a multidisciplinary approach (including non-hematologists like intensivists, cardiologists, and neurologists whose educational needs are addressed in this course), EHA has made this module accessible by everyone.


Read more

Off-the-Shelf CAR T-Cell Products Show Potential in DLBCL

  Nov 03 2020 Tagged CAR-T, LBCL, NHL

Loretta J. Nastoupil, MD, an assistant professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, discusses the use of off-the-shelf chimeric antigen receptor (CAR) T-cell products for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and other cancers.

Immunotherapy Web Featured Images 12

2020 CRI Virtual Immunotherapy Patient Summit: How immunotherapy works against c...

Immunotherapy is transforming treatment for many cancers and shows incredible promise for the future of all cancer care. But what is immunotherapy, and how does it work?

Read more
Immunotherapy Web Featured Images 9

New approach to fighting cancer could reduce costs and side effects

  Oct 23 2020 Tagged CAR-T

UniSA’s Future Industries Institute Ph.D. student Mona Elsemary has developed a microfluidic approach to purify CAR T-cells, the bioengineered immune cells that are the basis of groundbreaking cellular immunotherapy—a transformative cancer therapy that harnesses the power of a patient’s immune system to fight their cancer.

Read more
Immunotherapy Web Featured Images 10

Tecartus Recommended for EU Approval as CAR T-cell Therapy for Mantle Cell Lymph...

A committee of the European Medicines Agency (EMA) has recommended the conditional approval of Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL).

Read more

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off...

Human brain mural cells, essential for blood-brain barrier integrity, express CD19 and can then be potential off-tumor target for CD19-directed therapies, including CAR-T cells, suggesting a mechanism for associated neurotoxicity.
Read more
ImmunotherapyWebsite Images Featured 34

NextGen CARs: the race is on

In this issue of Blood, Tong et al present the preclinical and clinical development of an optimized, bivalent tandem CD20/CD19 chimeric antigen receptor (CAR) construct (see figure). Preclinically, they demonstrated dual-antigen specificity, enhanced immune synapse formation, and superior antitumor activity in vitro and in vivo in a murine xenograft model compared with alternative constructs generated from the same 2 single-chain variable fragment (scFv) regions derived from Leu-16 (anti-CD20) and FMC63 (anti-CD19) murine monoclonal antibodie.

Read more